Aggressive SM + AML has limited therapeutic options. Even a strong combination of decitabine-venetoclax-midostaurin has a transient effect on AML and a mitigated effect on SM. Larger series are required to identify the best therapeutic strategy.
A case of high-risk AML in a patient with advanced systemic mastocytosis
Fazio, Manlio;Vetro, Calogero;Duminuco, Andrea;Maugeri, Cinzia;Mauro, Elisa;Parrinello, Nunziatina Laura;Stagno, Fabio;Stella, Stefania;Palumbo, Giuseppe A;Di Raimondo, Francesco;Romano, Alessandra;
2023-01-01
Abstract
Aggressive SM + AML has limited therapeutic options. Even a strong combination of decitabine-venetoclax-midostaurin has a transient effect on AML and a mitigated effect on SM. Larger series are required to identify the best therapeutic strategy.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Clinical Case Reports - 2023 - Fazio - A case of high‐risk AML.pdf
accesso aperto
Tipologia:
Versione Editoriale (PDF)
Licenza:
Creative commons
Dimensione
4.26 MB
Formato
Adobe PDF
|
4.26 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
